BG63803B1 - Фармацевтичен състав за профилактика и лечение надиабетични усложнения - Google Patents

Фармацевтичен състав за профилактика и лечение надиабетични усложнения Download PDF

Info

Publication number
BG63803B1
BG63803B1 BG102633A BG10263398A BG63803B1 BG 63803 B1 BG63803 B1 BG 63803B1 BG 102633 A BG102633 A BG 102633A BG 10263398 A BG10263398 A BG 10263398A BG 63803 B1 BG63803 B1 BG 63803B1
Authority
BG
Bulgaria
Prior art keywords
treatment
pharmaceutically acceptable
prevention
compound
benzyl
Prior art date
Application number
BG102633A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102633A (en
Inventor
Yoshiharu Hayashi
Nobuharu Goto
Original Assignee
Yoshitomi Pharmaceutical Industries,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical Industries,Ltd. filed Critical Yoshitomi Pharmaceutical Industries,Ltd.
Publication of BG102633A publication Critical patent/BG102633A/xx
Publication of BG63803B1 publication Critical patent/BG63803B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
BG102633A 1995-12-27 1998-07-15 Фармацевтичен състав за профилактика и лечение надиабетични усложнения BG63803B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34016195 1995-12-27
PCT/JP1996/003776 WO1997024333A1 (fr) 1995-12-27 1996-12-24 Composes de prevention/traitement s'appliquant aux complications de diabetes

Publications (2)

Publication Number Publication Date
BG102633A BG102633A (en) 1999-09-30
BG63803B1 true BG63803B1 (bg) 2003-01-31

Family

ID=18334321

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102633A BG63803B1 (bg) 1995-12-27 1998-07-15 Фармацевтичен състав за профилактика и лечение надиабетични усложнения

Country Status (23)

Country Link
US (8) US6060496A (fr)
EP (2) EP0881218B1 (fr)
JP (1) JP3448869B2 (fr)
KR (2) KR100471351B1 (fr)
CN (2) CN1159009C (fr)
AT (1) ATE252563T1 (fr)
AU (1) AU716332B2 (fr)
BG (1) BG63803B1 (fr)
BR (1) BR9612316A (fr)
CA (1) CA2241856C (fr)
CZ (1) CZ294485B6 (fr)
DE (1) DE69630465T2 (fr)
EE (1) EE03524B1 (fr)
ES (1) ES2210399T3 (fr)
HK (1) HK1015777A1 (fr)
HU (1) HUP0000422A3 (fr)
IL (1) IL125104A (fr)
IS (1) IS4784A (fr)
MX (1) MX9805317A (fr)
NO (1) NO316494B1 (fr)
NZ (1) NZ324454A (fr)
RU (1) RU2173148C2 (fr)
WO (1) WO1997024333A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE252563T1 (de) * 1995-12-27 2003-11-15 Mitsubishi Pharma Corp Vorsorge-/heilmittel fur die komplikationen von diabetes
EP1186296B1 (fr) * 1999-05-25 2007-04-18 Mitsubishi Pharma Corporation Promoteurs de l'expression de la glycoproteine associee a la myeline (mag)
US6482844B1 (en) * 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
AU2001215513A1 (en) * 2000-11-24 2002-06-03 Toyo Shinyaku Co., Ltd. Foods containing young wheat leaf powder
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
EP1535077A2 (fr) * 2002-08-29 2005-06-01 University Of Florida Research Foundation, Inc. Equilibre des prostaglandines altere par mediation de cox-2 dans les complications liees au diabete
GB0314945D0 (en) * 2003-06-26 2003-07-30 Black & Decker Inc Vacuum cleaner
EP2234608A2 (fr) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
RU2741715C1 (ru) * 2020-03-20 2021-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ прогнозирования формирования микрососудистых осложнений сахарного диабета 2 типа

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK531479A (da) * 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS61277670A (ja) * 1985-06-03 1986-12-08 Yoshitomi Pharmaceut Ind Ltd イミダゾ−ル誘導体
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
JPS6147477A (ja) * 1984-08-14 1986-03-07 Kowa Co 新規１，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
JPS63119425A (ja) * 1986-11-07 1988-05-24 Yoshitomi Pharmaceut Ind Ltd 免疫機能改善薬
JPS63310825A (ja) * 1987-06-03 1988-12-19 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 医薬に有用な二環式化合物のｎ−イミダゾリル誘導体
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
WO1990012009A1 (fr) 1989-03-31 1990-10-18 Kyoto Pharmaceutical Industries, Ltd. Nouveaux derives d'imidazole, leur production, et leurs emplois comme medicaments
JPH037281A (ja) * 1989-03-31 1991-01-14 Kyoto Yakuhin Kogyo Kk 新規イミダゾール誘導体およびその医薬用途
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
ATE252563T1 (de) 1995-12-27 2003-11-15 Mitsubishi Pharma Corp Vorsorge-/heilmittel fur die komplikationen von diabetes

Also Published As

Publication number Publication date
US6258834B1 (en) 2001-07-10
US20060148875A1 (en) 2006-07-06
CZ294485B6 (cs) 2005-01-12
DE69630465D1 (de) 2003-11-27
HUP0000422A2 (hu) 2001-04-28
CA2241856C (fr) 2006-10-17
CN1209122A (zh) 1999-02-24
EP0881218A1 (fr) 1998-12-02
KR19990064262A (ko) 1999-07-26
CN1324618A (zh) 2001-12-05
NO982988D0 (no) 1998-06-26
US6060496A (en) 2000-05-09
IS4784A (is) 1998-06-26
US20050239856A1 (en) 2005-10-27
KR100471351B1 (ko) 2005-03-14
CN1092645C (zh) 2002-10-16
EP0881218A4 (fr) 1999-01-27
BR9612316A (pt) 1999-07-13
EP1394151A1 (fr) 2004-03-03
KR100443891B1 (ko) 2004-10-14
IL125104A0 (en) 1999-01-26
NZ324454A (en) 2000-09-29
EE03524B1 (et) 2001-10-15
ES2210399T3 (es) 2004-07-01
CA2241856A1 (fr) 1997-07-10
DE69630465T2 (de) 2004-07-22
MX9805317A (es) 1998-10-31
HUP0000422A3 (en) 2001-06-28
US20030130332A1 (en) 2003-07-10
HK1015777A1 (en) 1999-10-22
EE9800208A (et) 1998-12-15
BG102633A (en) 1999-09-30
CN1159009C (zh) 2004-07-28
NO982988L (no) 1998-08-26
WO1997024333A1 (fr) 1997-07-10
US20040171663A1 (en) 2004-09-02
NO316494B1 (no) 2004-02-02
CZ9802012A3 (cs) 1998-12-16
IL125104A (en) 2002-12-01
RU2173148C2 (ru) 2001-09-10
ATE252563T1 (de) 2003-11-15
US20020169194A1 (en) 2002-11-14
JP3448869B2 (ja) 2003-09-22
EP0881218B1 (fr) 2003-10-22
US20010036957A1 (en) 2001-11-01
AU1173597A (en) 1997-07-28
AU716332B2 (en) 2000-02-24
KR20040045002A (ko) 2004-05-31

Similar Documents

Publication Publication Date Title
EP2616066B1 (fr) Promédicaments de type ester de [3-(1-(1h-imidazol-4-yl)éthyl)-2-méthylphényl]méthanol pour le traitement de maladies rétiniennes
KR20020050257A (ko) Ａｃａｔ 저해제에 의한 플라크 파열의 방지
US20060148875A1 (en) Agent for prophylaxis and treatment of diabetic complications
DE69425085T2 (de) Angiotensin II Antagonisten als prophylaktisches und therapeutisches Mittel für Nierenkrankheiten
KR20060111898A (ko) 지질-풍부-플라크의 안정화 방법 및 파열 예방방법
EP3730138B1 (fr) Combinaison de sepetaprost et de ripasudil pour l'utilisation dans la prophylaxie ou le traitement du glaucome ou de l'hypertension oculaire
US11369601B2 (en) Prophylactic or therapeutic agent for pulmonary hypertension comprising mebendazole and/or itraconazole or salt thereof
EP3730143A1 (fr) Association de l'omidénépag
US7312239B2 (en) Medicament for prevention and/or therapy of arterial wall disorder
JP2003221334A (ja) 糖尿病性合併症の予防・治療剤
JPWO2003068263A1 (ja) 高血圧症治療薬
JP2002535369A (ja) 糖尿病を治療するための組成物及び方法
JP2001328939A (ja) 血糖降下剤